In addition to its well-characterized role in the activation of the immune response via the IRF3/NF-KB pathway [21, 22], TLR3 is emerging as a potential anti-tumor target in cancers, due to its ability to induce different death signals, depending on the cellular context [11]. This evidence concerns the gene NFKB1 and cancer.